Total Payments
$90,073
2024 Payments
$7,353
Companies
43
Transactions
680
Medicare Patients
7,760
Medicare Billing
$930,374
Payment Breakdown by Category
Other$53,814 (59.7%)
Consulting$19,679 (21.8%)
Food & Beverage$13,127 (14.6%)
Travel$3,193 (3.5%)
Education$261.16 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,814 | 41 | 59.7% |
| Consulting Fee | $19,679 | 20 | 21.8% |
| Food and Beverage | $13,127 | 582 | 14.6% |
| Travel and Lodging | $3,193 | 31 | 3.5% |
| Education | $261.16 | 6 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mylan Specialty L.P. | $78,641 | 178 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,106 | 146 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,579 | 96 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,256 | 51 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $979.84 | 35 | $0 (2023) |
| Mylan Inc. | $662.50 | 1 | $0 (2021) |
| Philips Electronics North America Corporation | $541.57 | 28 | $0 (2023) |
| Insmed, Inc. | $384.10 | 11 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $339.33 | 12 | $0 (2024) |
| GENZYME CORPORATION | $195.43 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,353 | 46 | Mylan Specialty L.P. ($6,694) |
| 2023 | $11,779 | 66 | Mylan Specialty L.P. ($10,580) |
| 2022 | $15,469 | 79 | Mylan Specialty L.P. ($14,210) |
| 2021 | $8,322 | 94 | Mylan Specialty L.P. ($6,033) |
| 2020 | $14,199 | 90 | Mylan Specialty L.P. ($12,991) |
| 2019 | $29,782 | 148 | Mylan Specialty L.P. ($27,996) |
| 2018 | $1,699 | 82 | AstraZeneca Pharmaceuticals LP ($517.07) |
| 2017 | $1,471 | 75 | AstraZeneca Pharmaceuticals LP ($339.87) |
All Payment Transactions
680 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $7.68 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/05/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,862.88 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Travel and Lodging | In-kind items and services | $329.78 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Travel and Lodging | Cash or cash equivalent | $102.09 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/12/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $37.44 | General |
| Category: HFCWO | ||||||
| 11/11/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $61.89 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/05/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: RESPIRATORY | ||||||
| 10/15/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/14/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Rare Disease | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Respiratory | ||||||
| 09/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Immunology | ||||||
| 08/21/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $32.11 | General |
| Category: Inflammation | ||||||
| 08/20/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $6.52 | General |
| Category: Narcoplepsy | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Respiratory | ||||||
| 08/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: RESPIRATORY | ||||||
| 07/25/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $309.50 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/19/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $619.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/11/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $7.80 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/08/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,353 | 2,954 | $414,295 | $223,627 |
| 2022 | 20 | 2,597 | 3,271 | $462,095 | $252,294 |
| 2021 | 16 | 1,415 | 2,073 | $385,240 | $234,076 |
| 2020 | 16 | 1,395 | 2,137 | $376,096 | $220,377 |
Total Patients
7,760
Total Services
10,435
Medicare Billing
$930,374
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 385 | 606 | $103,020 | $62,463 | 60.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 115 | 205 | $66,625 | $36,627 | 55.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 143 | 194 | $46,560 | $27,524 | 59.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 150 | 156 | $42,120 | $22,550 | 53.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 128 | 216 | $20,520 | $14,242 | 69.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 98 | 124 | $17,920 | $12,355 | 68.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 400 | 491 | $39,280 | $11,031 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 57 | 57 | $18,525 | $10,326 | 55.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $10,560 | $5,714 | 54.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 104 | 104 | $8,275 | $5,028 | 60.8% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 104 | 104 | $6,240 | $3,815 | 61.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 104 | 105 | $10,445 | $3,345 | 32.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $4,180 | $2,400 | 57.4% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 120 | 126 | $4,410 | $1,212 | 27.5% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 60 | 64 | $1,920 | $1,144 | 59.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 121 | 127 | $4,445 | $890.33 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $1,440 | $819.03 | 56.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 95 | 98 | $4,410 | $782.25 | 17.7% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 2023 | 11 | 14 | $630.00 | $417.06 | 66.2% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 19 | 23 | $460.00 | $359.95 | 78.3% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 21 | 21 | $630.00 | $311.01 | 49.4% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 40 | 41 | $1,680 | $271.20 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 332 | 487 | $116,880 | $70,610 | 60.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 136 | 300 | $97,500 | $55,458 | 56.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 304 | 373 | $63,410 | $37,873 | 59.7% |
About Dr. Ryan Reber, D.O
Dr. Ryan Reber, D.O is a Internal Medicine healthcare provider based in Wynnewood, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2009. The National Provider Identifier (NPI) number assigned to this provider is 1134352255.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Reber, D.O has received a total of $90,073 in payments from pharmaceutical and medical device companies, with $7,353 received in 2024. These payments were reported across 680 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($53,814).
As a Medicare-enrolled provider, Reber has provided services to 7,760 Medicare beneficiaries, totaling 10,435 services with total Medicare billing of $930,374. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Pulmonary Disease
- Location Wynnewood, PA
- Active Since 08/25/2009
- Last Updated 09/14/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1134352255
Products in Payments
- Yupelri (Drug) $64,611
- YUPELRI (Drug) $13,224
- XARELTO (Drug) $979.84
- BREZTRI (Drug) $700.05
- TRELEGY ELLIPTA (Drug) $658.77
- SYMBICORT (Drug) $644.69
- FASENRA (Drug) $503.49
- DUPIXENT (Biological) $500.01
- BEVESPI AEROSPHERE (Drug) $495.56
- FASENRA (Biological) $471.81
- STIOLTO RESPIMAT (Drug) $457.36
- NUCALA (Biological) $446.57
- Arikayce (Drug) $384.10
- OFEV (Drug) $303.84
- (8874) inCourage (Device) $296.93
- TEZSPIRE (Biological) $254.61
- ANORO (Drug) $213.09
- Xolair (Biological) $164.46
- SPIRIVA RESPIMAT (Drug) $161.18
- BREO (Drug) $150.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Wynnewood
Dr. Bonnie Goldmann, M.d, M.D
Internal Medicine — Payments: $127,503
Internal Medicine $127,503
Amanulla Khaji
Internal Medicine — Payments: $82,548
Internal Medicine $82,548
Dr. David Cohen, Md, MD
Internal Medicine — Payments: $41,001
Internal Medicine $41,001
Dr. M Susan Burke, Md, MD
Internal Medicine — Payments: $40,158
Internal Medicine $40,158
Hyon Ju Park, Md, MD
Internal Medicine — Payments: $13,459
Internal Medicine $13,459
Dr. Amy Smith, M.d, M.D
Internal Medicine — Payments: $12,217
Internal Medicine $12,217